ate last year, the Colombian Health Ministry unilaterally lowered the price of a Novartis cancer drug by 44 percent, a controversial step that underscored growing tensions between cash-strapped governments and the pharmaceutical industry. Now, though, a different branch of the Colombian government is trying to make it harder for such a move to occur again.

The Ministry of Trade, Industry, and Tourism earlier this month released a draft decree that would establish additional procedures before the government could either unilaterally cut the price of a medicine or issue a compulsory license, which would allow the government to sidestep patents held by a brand-name drug maker and allow another company to make a lower-cost version.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.